Nora-Christina Krau1, Nina-Sophie Lünstedt1, Sandra Freitag-Wolf2, Doreen Brehm1, Rainer Petzina3, Georg Lutter3,4, Peter Bramlage5, Astrid Dempfle2, Norbert Frey1,4, Derk Frank1,4. 1. Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Campus Kiel, Germany. 2. Institute of Medical Informatics and Statistics, University Hospital Schleswig-Holstein, Campus Kiel, Germany. 3. Department of Cardiac and Vascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Germany. 4. DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany. 5. Institute for Pharmacology and Preventive Medicine, Mahlow, Germany.
Abstract
AIMS: Transcatheter aortic valve implantation (TAVI) has emerged as a treatment of aortic stenosis in patients at high surgical risk. However, risk stratification in this elderly population is challenging, as patients at extreme risk might not benefit from TAVI. While several clinical criteria have been proposed for estimating the outcome, prediction of individual risk remains difficult. Therefore, our aim was to assess the prognostic value of the biomarker growth differentiation factor 15 (GDF15). METHODS AND RESULTS: Over a 2.9-year period, we prospectively enrolled 217 patients undergoing TAVI. Clinical parameters, risk scores, and biomarkers (NT-proBNP and GDF15) were measured at baseline. The primary endpoint was survival time; prognostic factors were analysed by Cox regression analysis. Mean age of study participants was 81.8 ± 6.0 years. Median Logistic EuroSCORE was 20.1 (Q1-Q3 13.6-32.6). Thirty-day mortality was 6.9%; 30.4% of the patients died during follow-up [median 349 days (Q1-Q3 106-660)]. Median pre-procedural GDF15 values were 2256 pg/mL (1585-3082). High GDF15 levels were associated with numerous factors that could contribute to poor outcome. Analyses comparing the upper quartile with the lower three quartiles for biomarker levels revealed a hazard ratio (HR) of increased GDF15 for adverse outcome of 2.4 [95% confidence interval (CI) 1.5-3.9, P < 0.001]. Of note, in multiple analyses, elevated GDF15 levels were superior to NT-proBNP for predicting negative outcome (adjusted HR of GDF15 1.97, 95% CI 1.2-3.3; P = 0.009). CONCLUSION: Elevated GDF15 levels were superior to NT-proBNP for TAVI risk stratification and provided additional prognostic information. Thus, patient selection for TAVI may benefit from measurement of GDF15.
AIMS: Transcatheter aortic valve implantation (TAVI) has emerged as a treatment of aortic stenosis in patients at high surgical risk. However, risk stratification in this elderly population is challenging, as patients at extreme risk might not benefit from TAVI. While several clinical criteria have been proposed for estimating the outcome, prediction of individual risk remains difficult. Therefore, our aim was to assess the prognostic value of the biomarker growth differentiation factor 15 (GDF15). METHODS AND RESULTS: Over a 2.9-year period, we prospectively enrolled 217 patients undergoing TAVI. Clinical parameters, risk scores, and biomarkers (NT-proBNP and GDF15) were measured at baseline. The primary endpoint was survival time; prognostic factors were analysed by Cox regression analysis. Mean age of study participants was 81.8 ± 6.0 years. Median Logistic EuroSCORE was 20.1 (Q1-Q3 13.6-32.6). Thirty-day mortality was 6.9%; 30.4% of the patients died during follow-up [median 349 days (Q1-Q3 106-660)]. Median pre-procedural GDF15 values were 2256 pg/mL (1585-3082). High GDF15 levels were associated with numerous factors that could contribute to poor outcome. Analyses comparing the upper quartile with the lower three quartiles for biomarker levels revealed a hazard ratio (HR) of increased GDF15 for adverse outcome of 2.4 [95% confidence interval (CI) 1.5-3.9, P < 0.001]. Of note, in multiple analyses, elevated GDF15 levels were superior to NT-proBNP for predicting negative outcome (adjusted HR of GDF15 1.97, 95% CI 1.2-3.3; P = 0.009). CONCLUSION: Elevated GDF15 levels were superior to NT-proBNP for TAVI risk stratification and provided additional prognostic information. Thus, patient selection for TAVI may benefit from measurement of GDF15.
Authors: Juyong Brian Kim; Yukari Kobayashi; Kegan J Moneghetti; Daniel A Brenner; Ryan O'Malley; Ingela Schnittger; Joseph C Wu; Gillian Murtagh; Agim Beshiri; Michael Fischbein; D Craig Miller; David Liang; Alan C Yeung; Francois Haddad; William F Fearon Journal: Circ Cardiovasc Interv Date: 2017-12 Impact factor: 6.546
Authors: Frederique E C M Peeters; Elton A M P Dudink; Bob Weijs; Larissa Fabritz; Winnie Chua; Bas L J H Kietselaer; Joachim E Wildberger; Steven J R Meex; Paulus Kirchhof; Harry J G M Crijns; Leon J Schurgers Journal: Front Cell Dev Biol Date: 2020-07-10
Authors: Jonas Neuser; Paolo Galuppo; Daniela Fraccarollo; Jens Willig; Tibor Kempf; Dominik Berliner; Johann Bauersachs; Julian Daniel Widder Journal: PLoS One Date: 2017-08-22 Impact factor: 3.240
Authors: Matthias Lutz; Nora von Ingersleben; Moritz Lambers; Mark Rosenberg; Sandra Freitag-Wolf; Astrid Dempfle; Georg Lutter; Johanne Frank; Peter Bramlage; Norbert Frey; Derk Frank Journal: Open Heart Date: 2017-06-10
Authors: Hatim Seoudy; Johanne Frank; Markus Neu; Nathalie Güßefeld; Yannic Klaus; Sandra Freitag-Wolf; Moritz Lambers; Georg Lutter; Astrid Dempfle; Ashraf Yusuf Rangrez; Christian Kuhn; Norbert Frey; Derk Frank Journal: J Am Heart Assoc Date: 2019-02-05 Impact factor: 5.501